You are here:Home-Inhibitors & Agonists-Cytoskeleton/Cell Adhesion Molecules-Myosin

Request The Product List ofMyosin Myosin

Cat. No. Product Name CAS No. Information
PC-43535

Blebbistatin S enantiomer

856925-71-8 Blebbistatin S enantiomer ((S)-(-)-Blebbistatin) is the S enantiomer of blebbistatin, which is a potent and selective myosin II inhibitor with IC50 of 0.5-5 uM; inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly, inhibits pancreatic adenocarcinoma cellular invasiveness; inhibits some myosin II-independent processes and that blebbistatin inhibits other activities in the absence of myosin II.
PC-63125

BHC

342387-19-3 BHC (Myosin inhibitor BHC) is a small-molecule screen of skeletal muscle myosin inhibitor that suppresses movements without affecting membrane currents; selectively blocks nerve-evoked muscle contraction without affecting neurotransmitter release.
PC-62887

ML-9 hydrochloride

105637-50-1 ML-9 hydrochloride is a potent, ATP-competitive myosin light chain kinase (MLCK) inhibitor with Ki of 3.8 uM, inhibits Store-operated Ca2+ entry (SOCE) in a variety of cell lines; also inhibits PKA and PKC with Ki of 32 and 54 uM; inhibits STIM1-plasma membrane interactions and inhibits TRPC6 channels via a mechanism independent of inhibition of MLCK activity.
PC-62326

MYK-461

1642288-47-8 MYK-461 (SAR 439152) small molecule that reduces contractility by decreasing the ATPase activity of the cardiac myosin heavy chain, inhibits α and β isoforms of cardiac myosin with similar activity (IC50=0.3 uM); suppresses the development of ventricular hypertrophy, cardiomyocyte disarray, and myocardial fibrosis and attenuates hypertrophic and profibrotic gene expression in mice harboring heterozygous human mutations in the myosin heavy chain.

Other Indication

Phase 2 Clinical

PC-60047

Mavacamten

1642288-47-8 A small molecule that reduces contractility by decreasing the ATPase activity of the cardiac myosin heavy chain; inhibits α and β isoforms of cardiac myosin with similar activity (IC50=0.3 uM); suppresses the development of ventricular hypertrophy, cardiomyocyte disarray, and myocardial fibrosis and attenuates hypertrophic and profibrotic gene expression in mice harboring heterozygous human mutations in the myosin heavy chain.

Other Indication

Phase 2 Clinical

PC-45036

BTS

1576-37-0 A highly specific myosin II ATPase inhibitor; inhibits the Ca2+-stimulated S1 ATPase, and reversibly blocked gliding motility; inhibits isometric Ca2+-activated tension with IC50 of 3 uM in glycerol-extracted fibres from rabbit psoas muscle; specific and no activity for platelet myosin II.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com